October 14, 2019 BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated company, focused on developing regenerative therapies leveraging its proprietary hyaluronic acid (“HA”) technology platform to provide treatments across the joint preservation and restoration continuum of care, today announced the appointment of Mira Leiwant to the newly created position of Vice President of Regulatory Affairs, Quality …